Supernus Pharmaceuticals SUPN Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's total liabilities & equity?
- Supernus Pharmaceuticals (SUPN) reported total liabilities & equity of $1.5B in Q1 2026.
- How has Supernus Pharmaceuticals's total liabilities & equity changed year-over-year?
- Supernus Pharmaceuticals's total liabilities & equity increased by 11.4% year-over-year, from $1.35B to $1.5B.
- What is the long-term trend for Supernus Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total liabilities & equity has grown at a -0.7% compound annual growth rate (CAGR), from $1.5B to $1.45B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.